10 March 2021 in Statistics in Biopharmaceutical Research
Real-world evidence (RWE), derived from Data from “real-world” clinical practice and medical product utilization, is an increasingly important source of evidence that holds great potential to increase efficiency and improve clinical development and life cycle management of medical products. Regulatory agencies, public-private partnerships and health technology assessment organizations have launched major initiatives and released guidance to address considerations in the use of RWE to inform regulatory decision making. However, many challenges remain on how RWE could be best utilized for various types of regulatory decisions from statistical perspectives. To address the relevant statistical challenges, a working group under the auspices of the ASA Biopharmaceutical Section was established. This article reviews the biostatistical challenges and methods for the use of RWE for medical product development. There are two companion papers as the output from the same working group that address focused topics. The paper by Chen et al. (2020) provides the current landscape on the use of RWE to inform clinical study design and analysis, and the paper by Ho et al. (2020) presents a review of causal inference framework for design and analysis of studies using RWE.
17 February 2020 in Clinical Trials
Real-world data and evidence provide the potential to address the effectiveness and safety of drugs. The U.S. Food & Drug Administration has initiated a program to evaluate the potential use of real-world evidence for regulatory uses. Whether a study is designed for regulatory purposes or for other purposes, existing regulation and guidance provide a reference for high-quality studies. Clarifying the study objectives and the role of real-world data in the study are important considerations. Robustness and transparency of the analysis allow for greater understanding and acceptance of the study results.
7 October 2022 in Statistics in Biopharmaceutical Research
A Real-World Evidence (RWE) scientific working group of the American Statistical Association Biopharmaceutical Section has been reviewing the statistical considerations for the generation of real-world evidence to support regulatory decision making. As part of the effort, the working group is addressing the fitness-for-use of real-world data (RWD). RWD may be used in a variety of ways and study designs including in randomized studies, externally controlled studies, and purely observational studies. The use of RWD poses unique issues surrounding study integrity, transparency, and reproducibility. Rule-based methods and machine learning approaches can be used to extract key data elements from RWD sources. In some cases, multiple sources of data may be linked to obtain the necessary study data. Missing data may have unique considerations in the RWD sources, since data elements are collected for the practice of medicine and are not protocol driven. Lack or imperfect capture of some information in an RWD source may lead to multiple biases that threaten the fitness-for-use of an RWD source, including information bias, selection bias, and confounding. Validation studies and quantitative bias assessment can be used to assess the potential bias. The working group proposes a data-driven approach framework for determining the fit-for-use of RWD.
1 January 2013 in Journal of Biopharmaceutical Statistics
While randomized, well-controlled, clinical trials have been viewed as the gold standard in the evaluation of medical products, including drugs, biological products, and medical devices, it is not uncommon for safety assessment to be performed using observational studies, for ethical or practical reasons. In observational studies, various biases could be introduced in every stage and aspect of study, and consequently the resulting statistical inference may carry a lower level of scientific assurance, compared to randomized trials. To ensure the objectivity of study design and interpretability of the results, it is critical to address the challenges of such studies. In this paper, we share regulatory considerations on the prospective design of observational studies to address safety issues using propensity score methodology.
1 November 1997 in Fire and Materials
27 April 2025 in Clinical Pharmacology & Therapeutics